Login to Your Account

Clinic Roundup

Thursday, October 10, 2013

• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said the Children’s Oncology Group (COG) has opened enrollment in a Phase I trial with MORAb-004 in pediatric patients with relapsed/refractory solid tumors. The open-label study will assess the safety, tolerability and pharmacokinetics of MORAb-004 administered in weekly intravenous infusions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription